Skip to main content
  • nl
  • fr
  • en
Other official information and services: www.belgium.be
Logo of the Belgian Federal Authorities
FAMHP
Your medicine and health products
  • About the FAMHP
  • Jobs
  • Publications
  • Press
  • Contact
  • Complaints
  • Webportal
  • Home
  • Human medicines
  • Veterinary medicines
    • Medicines
    • Particular products
      • Raw materials
      • Specially reglemented substances
        • Narcotics and psychotropics
        • Precursors
        • Hormonal substances and other
        • GMO
      • Grey area
    • Health products
  • Information for the public
  • Notification of adverse reactions or incidents
  • Home
  • Veterinary medicines
  • Particular products
  • Specially reglemented substances
  • Medicines
    • Medicines
  • Particular products
    • Raw materials
    • Specially reglemented substances
    • Grey area
  • Health products
    • Medical devices and their accessories

Specially reglemented substances

  • Narcotics and psychotropics
    • Legislation - Substances
    • Activity licence
    • End user licence
    • Private Licence
    • Import - Export
    • Letter Of Non Objection (LONO)
    • Narcotic drugs order forms
    • Destruction of products
  • Precursors
    • Agreement - Registration
    • Authorisation import/export
    • Central contact point
    • Legislation - Background
  • Hormonal substances and other
    • Generalities
    • Authorisation
    • Change of the authorisation
    • Letter Of No Objection (LONO)
  • GMO
    • Definition
    • Clinical trials
    • Public consultation
Last updated on 19/09/2013

Notification of adverse reactions or incidents

PIL and SPC
of a medicine

(PIL: patient information leaflet SPC: summary of product characteristics)

Search

News

18/06/2018
Give your opinion on a clinical trial with a genetically modified medicinal product against oral mucositis in patients with cancer
04/06/2018
ESSURE sterilisation device permanently withdrawn from the market in the European Union
30/05/2018
Telephone accessibility of the Call centre Marketing Authorisation will change
25/05/2018
PRAC May 2018 – Recommendation to suspend hydroxyethyl-starch (HES) solutions for infusion, new measures for Esmya, end of the review of Zinbryta and precautionary advice on HIV medicine
All news

© 2016 - FAMHP

  • Site map
  • Disclaimer
  • Complaints
  • Contact